In its response to the statement of objections, Aventis argues that as regards methylglucamine, only legitimate contacts relating to occasional product shortages took place between the companies prior to 1990. The statements of [Merck employee 3] and [Merck employee 1] do not provide proof of illegitimate contacts prior to 1990 and the reliability of the rumours heard by [Merck employee 4 ] and [Merck employee 5] are highly questionable(42).
Recital 66, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002